IndraLab

Statements

USP9X inhibits cisplatin. 3 / 3
| 3
reach
"However, USP9X knockdown increased NSCLC cell sensitivity to cisplatin, as it did with WP1130."
28446729
reach
"Inhibition of USP9X increased cisplatin and doxorubicin sensitivity in estrogen receptor-negative breast cancer cells and hepatocellular carcinoma cells, respectively [215,242]."
34814083
reach
"Knockdown of USP9X reverses cisplatin resistance by decreasing beta-catenin expression in nasopharyngeal carcinoma cells."
34097426